Dapagliflozin/Rosuvastatin (Cmg Pharmaceutical)

达格列净/瑞舒伐他汀 (Cmg Pharmaceutical)

Report date: 2025/02/27 16:12:34

Base Information

Drug NameDapagliflozin/Rosuvastatin (Cmg Pharmaceutical)
Drug Alias NameCMG190303
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHMG-CoA reductase inhibitorsSodium/glucose cotransporter 2 inhibitors
TargetsHMG-CoA reductaseSodium/glucose cotransporter 2
Therapy Area/IndicationsDyslipidemiasDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCmg Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCmg Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDyslipidemiasDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A